Form 4: Terns Pharmaceuticals CEO Acquires Shares and Stock Options
SEC Form 4
Amy L. Burroughs, CEO of Terns Pharmaceuticals, reports the acquisition of common stock and stock options.
Summary
- Amy L. Burroughs, the CEO of Terns Pharmaceuticals, reported transactions involving the company's securities.
- On November 30, 2024, she acquired 510 shares of common stock at a price of $5.11 per share through the Employee Stock Purchase Plan.
- She also acquired options to purchase 1,075,000 shares of common stock on January 30, 2025, at an exercise price of $4.64.
- These options vest over four years from January 1, 2025, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock and option acquisitions by the CEO. The delayed reporting of the 510 shares is a minor negative, but overall, it's a standard transaction.
Positives
- The CEO's acquisition of shares and stock options could be interpreted as a positive signal, indicating confidence in the company's future performance.
Future Outlook
The vesting schedule of the stock options indicates a long-term incentive plan for the CEO, aligning her interests with the company's performance over the next four years.
Industry Context
Executive stock ownership and option grants are common practices in the pharmaceutical industry to incentivize leadership and align their interests with shareholder value. This filing reflects standard compensation practices.
Comparison to Industry Standards
- Executive compensation packages in the pharmaceutical industry typically include a mix of salary, stock options, and restricted stock units.
- The vesting schedule of these options is fairly standard, often spanning three to five years to encourage long-term commitment.
- Comparing the size of the option grant (1,075,000 shares) to similar companies would require analyzing their executive compensation disclosures.
Stakeholder Impact
- The CEO's increased stake in the company could positively influence investor confidence.
- Employees may view the CEO's stock ownership as a sign of commitment to the company's success.
Key Dates
| Date | Description |
|---|---|
| 11/30/2024 | Acquisition of 510 shares of common stock through the Employee Stock Purchase Plan. |
| 01/01/2025 | Vesting Commencement Date for stock options. |
| 01/30/2025 | Acquisition of options to purchase 1,075,000 shares of common stock. |
| 01/29/2035 | Expiration date of the acquired stock options. |
| 02/03/2025 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.